Phase 1 Study of Quizartinib
NCT02675478 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17
Last updated 2019-02-12
Summary
This is a dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of quizartinib for Japanese acute myeloid leukemia (AML) subjects.
Conditions
- Relapsed AML
- Refractory AML
Interventions
- DRUG
-
AC220
Sponsors & Collaborators
-
Daiichi Sankyo Co., Ltd.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 20 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-02-29
- Primary Completion
- 2018-11-13
- Completion
- 2018-11-13
- FDA Drug
- Yes
Countries
- Japan
Study Locations
More Related Trials
-
A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment
NCT04473664 ·Status: COMPLETED ·Phase: PHASE1
-
(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive
NCT02039726 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status
NCT00462761 ·Status: COMPLETED ·Phase: PHASE1
-
Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML
NCT03922100 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT06001788 ·Status: RECRUITING ·Phase: PHASE1
-
A Study to Determine the Absolute Oral Bioavailability of Quizartinib Using a Radiolabeled Microtracer in Healthy Subjects
NCT04796831 ·Status: COMPLETED ·Phase: PHASE1
-
A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT00923182 ·Status: COMPLETED ·Phase: PHASE1
-
A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment
NCT04112589 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia
NCT01564784 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of SKLB1028 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
NCT02859948 ·Status: UNKNOWN ·Phase: PHASE1
-
MK0457 in Patients With Leukemia (0457-003)
NCT00111683 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
NCT03162536 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Phase I Study of GNKG168 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)
NCT01035216 ·Status: TERMINATED ·Phase: PHASE1
-
Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes
NCT05426798 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
NCT05735184 ·Status: RECRUITING ·Phase: PHASE1
-
Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia
NCT06376162 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
NCT06618001 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT03516617 ·Status: RECRUITING ·Phase: PHASE2
-
Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes
NCT00981240 ·Status: COMPLETED ·Phase: PHASE1
-
A Clinical Trial to Evaluate Clifutinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia(AML)
NCT04827069 ·Status: COMPLETED ·Phase: PHASE1
-
A Clinical Study of SHP674 (Pegaspargase) in Participants With Newly Diagnosed, Untreated Acute Lymphoblastic Leukemia
NCT04067518 ·Status: COMPLETED ·Phase: PHASE2
-
Carfilzomib in Patients With Relapsed Acute Myeloid or Acute Lymphoblastic Leukemia
NCT01137747 ·Status: COMPLETED ·Phase: PHASE1
-
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
NCT04260022 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment
NCT04241549 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of QLF32101 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
NCT05703204 ·Status: UNKNOWN ·Phase: PHASE1